EGFR-directed tyrosine kinase inhibitors for non-small cell lung cancer

QR Code

EGFR-directed tyrosine kinase inhibitors for non-small cell lung cancer

Non-small cell lung cancer (NSCLC) accounts for approximately 85% of all lung cancer cases and remains a leading cause of cancer-related deaths globally. While conventional chemotherapy has provided modest benefits, its toxicity and limited efficacy have underscored the need for more precise treatme...

Full description

Bibliographic Details
Main Authors:	Fatin Nur Elyana Mohd Sidek, Muhammad Kumayl Abdulwahab, Rashidi Dzul Keflee, Mohammed Abdullah Alshawsh, Suzita Mohd Noor, Zarif Mohamed Sofian, Azhar Ariffin
Format:	Article
Language:	English
Published:	Penerbit Universiti Kebangsaan Malaysia 2025
Online Access:	http://journalarticle.ukm.my/25993/ http://journalarticle.ukm.my/25993/1/SML%2012.pdf

Similar Items

Case series of small cell lung cancer transformation post tyrosine kinase inhibitor failure
by: Chai, C.S., et al.
Published: (2017)

Small Cell Transformation and T790M Mutation as Coresistance Mechanisms for First-line Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI) Therapy Failure
by: Chee, Shee Chai
Published: (2017)

Self-assembling tyrosine kinase inhibitors for localised targeted delivery
by: Al-Ameedee, Mohammed
Published: (2017)

Case Series of Small Cell Lung Cancer Transformation as Resistance Mechanism to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor
by: Liam, C, et al.
Published: (2017)

An apoferritin-based drug delivery system for the tyrosine kinase inhibitor gefitinib
by: Kuruppu, Anchala I., et al.
Published: (2015)

Adaptive therapy to circumvent drug resistance to tyrosine kinase inhibitors in cancer: is it clinically relevant?
by: Hamdi, Amir Imran Faisal, et al.
Published: (2022)

Outcome of patients with advanced lung adenocarcinoma treated with first-line epidermal growth factor receptor tyrosine kinase inhibitors versus cytotoxic chemotherapy
by: Chai, Chee She
Published: (2015)

Benzalhydantoin derivative-based inhibitors of eight receptor tyrosine kinases: synthesis, in-vitro, and in-silico study
by: Muhammad Naufal,, et al.
Published: (2025)

An investigation into the effects of the epidermal growth factor receptor tyrosine kinase inhibitor "Gefitinib" on human breast cancer
by: Gutteridge, Eleanor
Published: (2010)

Effects of 4 multitargeted receptor tyrosine kinase inhibitors on regional hemodynamics in conscious, freely moving rats
by: Carter, Joanne J., et al.
Published: (2016)

Linifanib – a multi-targeted receptor tyrosine kinase inhibitor and a low molecular weight gelator
by: Marlow, Maria, et al.
Published: (2015)

Spectroscopic and molecular modeling studies on the interaction of tyrosine kinase inhibitors with human serum albumin / Md. Zahirul Kabir
by: Md. Zahirul , Kabir
Published: (2018)

Resistance mechanisms causing first-line epidermal growth factor receptor-tyrosine kinase inhibitor treatment failure
by: Chai, C.S., et al.
Published: (2017)

The effect of Oroxylum indicum leaves methanolic extract towards VCAM-1 expression on hela cells
by: Keflee, Rashidi Dzul
Published: (2016)

The effect of microrna targeting IL17RA in regulating the expression of RANKL and OPG in stem cells from human exfoliated deciduous teeth
by: Keflee, Rashidi Dzul
Published: (2018)

Molecular docking analysis on the designed benzimidazole derivatives as EGFR inhibitors: comparison between EGFR wild-type (EGFRWT) and T790M mutant
by: Nurul Awani Syazzira Jalil,, et al.
Published: (2023)

Characteristics of epidermal growth factor receptor (EGFR)-Mutated Non Small Cell Lung Carcinoma (NSCLC)-patients who developed resistance to first or second generation Egfrtyrosine Kinase Inhibitor (TKI) Therapy through T790M mutation / Vijayan Munusamy
by: Vijayan, Munusamy
Published: (2017)

Survival rate and prognostic factors of survival among chronic myeloid leukaemia adults after initiation of tyrosine kinase inhibitor therapy in Hospital Ampang, Selangor
by: Ali, Zakiah Bakar
Published: (2024)

Determination of gene expression of tyrosine kinase receptors (HER family) in FFPE tissue of colorectal adenocarcinoma
by: Othman @ Jaffar, Rosfayati, et al.
Published: (2015)

Effects of receptor tyrosine kinase inhibitors on VEGF165a- and VEGF165b-stimulated gene transcription in HEK-293 cells expressing human VEGFR2
by: Carter, Joanne J., et al.
Published: (2015)

Real-time analysis of the binding of fluorescent VEGF₁₆₅a to VEGFR2 in living cells: Effect of receptor tyrosine kinase inhibitors and fate of internalized agonist-receptor complexes
by: Kilpatrick, Laura E., et al.
Published: (2017)

Role of Focal Adhesion Tyrosine Kinases in GPVI-Dependent Platelet Activation and Reactive Oxygen Species Formation
by: Carrim, N., et al.
Published: (2014)

Inhibition of Spleen Tyrosine Kinase Potentiates Paclitaxel-Induced Cytotoxicity in Ovarian Cancer Cells by Stabilizing Microtubules
by: Yu, Yu, et al.
Published: (2015)

The focal adhesion kinase Pyk2 links Ca2+ signalling to Src family kinase activation and protein tyrosine phosphorylation in thrombin-stimulated platelets
by: Canobbio, I., et al.
Published: (2015)

A phase 2 trial of decreasing tyrosine kinase inhibitor dose in chronic myeloid leukaemia patients with stable major molecular response: data from the British DESTINY study
by: Clark, Richard E., et al.
Published: (2017)

The proline-rich tyrosine kinase Pyk2 regulates platelet integrin aIIbß3 outside-in signaling
by: Cipolla, L., et al.
Published: (2013)

Roles of Rho-associated kinase in lung cancer review
by: Zakaria, Muhammad Asyaari, et al.
Published: (2020)

A randomized control trial comparing peginterferon-α-2a versus observation after stopping tyrosine kinase inhibitor in chronic myeloid leukemia with deep molecular response for at least two years
by: Kuan, Jew-Win, et al.
Published: (2016)

Impaired thrombin-induced platelet activation and thrombus formation in mice lacking the Ca2+-dependent tyrosine kinase Pyk2
by: Canobbio, I., et al.
Published: (2013)

Src family tyrosine kinase Lyn mediates VWF GPIb-IX induced platelet activation via the cGMP signaling pathway
by: Yin, H., et al.
Published: (2008)

Approved and experimental small-molecule oncology kinase inhibitor drugs: a mid-2016 overview
by: Fischer, Peter M.
Published: (2017)

Development of an EGFR-targeted Drug Delivery System for Glioblastoma
by: Zhao, Zi-Ruo
Published: (2023)

Identification of potent new brain cancer EGFR inhibitor from usimine A and usimine B: computer-aided drug design perspective
by: Roney, Miah, et al.
Published: (2024)

The tyrosine kinase Pyk2 mediates the cross-talk between platelet integrins alpha 2 beta 1 and alpha IIb beta 3
by: Guidetti, G., et al.
Published: (2011)

The tyrosine kinase PYK2 mediates the cross-talk between platelet integrins alpha 2 beta 1 and alpha iib beta 3
by: Guidetti, G., et al.
Published: (2011)

Effects of small molecule inhibitors targeting PI3K, EGFR, IGF-1R, MTOR, SMAD3 and MEK in tube formation and 3-D spheroid assay
by: Ng, Chin Tat
Published: (2014)

Evaluation of transcriptional cyclin dependent kinase inhibitors as potential cancer therapeutics
by: Liu, Xiangrui
Published: (2012)

Design and synthesis of benzimidazole-based Rho kinase inhibitors for the treatment of glaucoma
by: Abbhi, V., et al.
Published: (2017)

Phosphoinositide 3-kinase pathway inhibitors: pharmacology, metabolism & drug development
by: Falasca, Marco
Published: (2011)

Dynamics of ligand and nanobody binding at CXCR4/EGFR complexes
by: Comez, Dehan
Published: (2025)